SAR Studies Leading to the Identification of a Novel Series of Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections That Display Efficacy in an Animal Infection Model by Leiris, Simon et al.
SAR Studies Leading to the Identification of a Novel Series of
Metallo-β-lactamase Inhibitors for the Treatment of Carbapenem-
Resistant Enterobacteriaceae Infections That Display Efficacy in an
Animal Infection Model
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ABSTRACT: The clinical effectiveness of carbapenem anti-
biotics such as meropenem is becoming increasingly
compromised by the spread of both metallo-β-lactamase
(MBL) and serine-β-lactamase (SBL) enzymes on mobile
genetic elements, stimulating research to find new β-lactamase
inhibitors to be used in conjunction with carbapenems and
other β-lactam antibiotics. Herein, we describe our initial
exploration of a novel chemical series of metallo-β-lactamase
inhibitors, from concept to efficacy, in a survival model using
an advanced tool compound (ANT431) in conjunction with
meropenem.
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A major public health concern for our age is the increasingresistance to antibiotics. The U.K. government recently
commissioned a review under Jim O’Neill1 that examined this
issue in depth and proposed structural changes to industry
practice, drug pricing, etc. in an attempt to redirect resources
to the problem. Similarly, in the United States, the CARB-X2
initiative, a jointly funded public-private partnership between
the Wellcome Trust and BARDA,3 is revitalizing research in
this area through various funding initiatives. In particular,
Gram-negative bacteria are becoming a major concern because
not only are they inherently more difficult to treat with
antibiotics due to entry and efflux issues but also the crucial
carbapenem class of β-lactam antibiotics is becoming less
clinically effective. As a consequence, major Gram-negative
pathogens are currently evolving toward pan-drug-resistant
phenotypes, whose potential global spread may lead to a
dramatic return to the pre-antibiotic era. A major resistance
mechanism to β-lactams antibiotics is represented by the
production of one or more β-lactamase enzymes, which
efficiently hydrolyze the amide bond of the β-lactam ring. β-
Lactamases belong to two structurally and mechanistically
unrelated families of enzymes,4 the serine-β-lactamases (SBLs;
classes A, C, and D), which use an active serine to cleave the β-
lactam in a covalent mechanism, and the metallo-β-lactamases
(MBLs; class B), which use metal ion catalysis to directly
hydrolyze the β-lactam without the formation of a covalent
intermediate. To counter the threat of emerging resistance, the
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Streptomyces clavuligerus natural product clavulanic acid (2), an
SBL inhibitor (Scheme 1), was introduced in 1981 as part of a
combination together with the β-lactam antibiotic amoxicillin
(as Augmentin),5 followed by tazobactam in 1992, combined
with piperacillin.6 More recently, there has been renewed
interest in the field of β-lactamase inhibitor discovery to
counter the threat from newer β-lactamases, which are not
inhibited by clavulanic acid or tazobactam, such as the
extended spectrum β-lactamases (ESBLs) and carbapenemases.
This has led to the development of two new synthetic classes
of inhibitors, namely the diazabicyclooctane (DBO) series, as
exemplified by avibactam7 (3), which is used in combination
with ceftazidime, and the boronates of generalized bicyclic
structure (4) plus monocyclic boronate vaborbactam8 (5),
which is used in combination with meropenem. However, both
3 and 5 are exclusively SBL inhibitors, whereas examples of
generalized structure (4) are known to have dual SBL and
MBL inhibitory activity,9 a novel finding that can be
rationalized at the molecular level.10 However, as of yet,
there are no MBL inhibitors in clinical use despite there being
a clear unmet medical need.11
The MBL family includes the clinically relevant B1 subfamily
containing the acquired IMP, VIM, and NDM subgroups of
allelic variants. Many classes of MBL inhibitors have been
reported in the research stage including bisthiazolidines, thiols,
tetrazoles, succinic acids, and hydroxamates.12
Recently Chen et al.13 reported novel MBL inhibitors (as
exemplified by 6) based on a pyridine-2-carboxylic acid (1)
scaffold, which was previously reported to be a modest
inhibitor of the Aeromonas hydrophila CphA MBL (Ki
[inhibition constant] = 6 μM).14 The CphA enzyme belongs
to the divergent B2 subclass of MBLs, which have a single Zn
ion in their active site and do not have the clinical significance
of subclass B1 MBLs (which instead coordinate two Zn ions in
the di-nuclear active site). These compounds have promising
activity in terms of both NDM-1 inhibition and potentiation
against clinical strains expressing NDM-1; however, the most-
active compound from this work (compound 6 in Scheme 1)
contains a lipophilic aniline, a moiety well-known to be
associated with clastogenic and carcinogenic effects.15
In this study, we also report on the design and optimization
of new MBL inhibitors starting from pyridine-2-carboxylic
acid; however, we have taken a very different medicinal
chemistry approach, leading to the identification of a
chemically distinct series with promising activity against
MBL-producing clinical isolates and drug-like properties,
which makes it suitable for further pharmaceutical develop-
ment.
■ RESULTS AND DISCUSSION
Derivatives of Pyridine-2-carboxylic Acid, Pan-MBL
Inhibitors. Although the biological activity of pyridine-2-
carboxylic acid (1) is relatively modest, its low molecular
weight and simple structure makes it an attractive starting
point for medicinal chemistry. From the work of Horsfall et
al.,14 biochemical and structural analyses clearly demonstrated
that pyridine-2-carboxylic acid (1) was a competitive inhibitor
of CphA. This mechanism of inhibition, relying on the
formation of a stable enzyme−inhibitor complex, was different
from that exhibited by its close bidentate analogue 2,6-
dipicolinic acid, which instead acts as a strong zinc chelator
and non-specifically inactivates metallo-enzymes. The latter
mechanism of action, also shown by EDTA16 and some natural
products,17 may produce significant off-target implications in
clinical use18 and be less effective against newer NDM variants,
which have evolved high-affinity Zn-binding and are therefore
less prone to inhibition by metal-chelating agents.19 Using
enzyme assays, we evaluated the potential of 1 to inhibit MBLs
other than CphA and were encouraged to find that it exhibited
an IC50 value of 17 μM against NDM-1, although there was no
significant activity against VIM-1 or IMP-1 enzymes. However,
1 showed no reduction of imipenem MIC when tested at
concentrations up to 1 mM on a laboratory strain of NDM-1-
producing Escherichia coli (DH5α/pLBII-NDM-1), presum-
ably due to lack of penetration into, or efflux from, the
periplasm (data not shown).
Because the X-ray structure of 2,4-pyridine dicarboxylic acid
in the MBL CphA clearly shows coordination of both the
carboxylate group at position 2 and the pyridine nitrogen to
the single Zn ion, coordinated by conserved residues Asp120,
Cys221, and His263, which form the so-called “Zn2” site
(Figure 1), we screened a number of related heterocyclic acids
with this structural feature. The modest inhibition of NDM-1
was seen with quinoline acid (7) and isoquinoline acid (11),
but no inhibition of the other two MBLs was detected at
concentration as high as 200 μM. Surprisingly, other
heterocyclic acids such as imidazole (8), pyrazine (9), and
pyridazine (10) showed no detectable inhibition. Given the
simplicity of the chemistry, compared with both the quinoline
and isoquinoline series, we considered pyridine-2-carboxylic
acid (1) to be a suitable starting point for a medicinal
chemistry program. Initially, this involved some array
chemistry, adding substituents to ethylpyridine-2-carboxylate
followed ester hydrolysis to give the acid (Scheme 2). The
short-term objective was to improve the inhibition spectrum of
the molecule and obtain whole cell synergistic activity, with the
longer-term objective being the discovery of a drug molecule
with good PK and efficacy.
We used standard synthetic routes to explore the activity of
biaryl analogues, amides, and sulfonamides at all available
positions of the parent structure 1 (Scheme 2 and
Supplementary Data). These array compounds were screened
against a panel of NDM-1, VIM-1, VIM-2, and IMP-1
Scheme 1. Representative Examples of β-Lactamase
Inhibitors: (1) Pyridine-2-carboxylic Acid (Picolinic Acid),
(2) Clavulanic Acid, (3) Avibactam, (4) Generalized Cyclic
Boronate, (5) Vaborbactam, and (6) 2,6-Pyridine
Dicarboxylic Acid Derivative
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enzymes. In terms of relative importance, we were most
interested in NDM-1 and VIM-1 because of their widespread
prevalence in Enterobacteriaceae (IMP-1 is not so widespread
geographically, and VIM-2 is almost exclusively found in
Pseudomonas).20 The results of this initial array work are
reported in Table 1. Compounds of interest were progressed to
a whole-cell meropenem potentiation assay to investigate if the
inhibitor could restore the antibacterial activity of meropenem
against resistant strains, where the resistance was attributable
to the production of an MBL enzyme. Initially, we used
laboratory strains transformed with plasmids expressing only
the MBL resistance genes; however, early on, we switched to
using clinical carbapenem-resistant Enterobacteriaceae (CRE)
isolates to evaluate the synergistic activity of the compounds
because these presented a greater challenge that was more
representative of the clinical situation.
Biaryl analogues such as compounds 12 to 16 were
essentially inactive and were not pursued further. Encourag-
ingly, amide groups were tolerated with respect to NDM-1
inhibition at all four positions on the pyridine ring. One of the
earliest compounds prepared, amide 17, showed the promising
low micromolar inhibition of NDM-1 as well as detectable
inhibition of all three enzymes at higher concentrations,
representing an interesting, although modest, broad-spectrum
inhibitor. Related amides such as 18 proved, by contrast,
inactive at a concentration of up to 200 μM on all tested
enzymes, whereas 17 and 23 represented a significant advance
from 1, which only had modest activity against the NDM-1
enzyme.
We also explored the sulfonamide substituent because, due
to the different hybridization state of the sp3 sulfur compared
to sp2 carbon, sulfonamides access alternative regions of space
and H-bonding opportunities as compared with the amides.
Surprisingly strong inhibition of VIM-2 was observed by
certain sulfonamides such as 32 and 43. The modest but
genuine MBL inhibition achieved against both NDM-1 and
VIM-1 represented a significant advance over the starting
position of 1, stimulating further efforts to improve the
potency and spectrum of the series.
X-ray Crystallography Revealing of a Novel Binding
Mode to the VIM-2 MBL. The mode of binding of certain
inhibitors was ascertained by X-ray crystallography experi-
ments. A crystal structure of VIM-2 in complex with the simple
phenyl sulfonamide 32 revealed interesting features of its
binding modality (Figure 2). Notably the pyridine nitrogen
and the carboxylate group of the inhibitor were bound to a
single Zn atom (Zn2, coordinated by conserved residues
Asp120, Cys221, and His263). Inhibitor binding also resulted
in the displacement of two crystallographic water molecules
found in the native structure but, interestingly, not the so-
called “bridging” water molecule coordinated by the two active
site Zn ions, which provides the nucleophile attacking the
carbonyl carbon of the β-lactam substrate. Taken with the
enzyme inhibition data, this structural information is fully in
accord with a reversible competitive mode of action and not a
general chelation effect (whereby the ligand removes metal
ions from solution eventually stripping metal ions from the
enzyme through equilibrium processes). Although inhibitor
binding did not alter the tertiary structure of the enzyme,
several side chains movements were observed, such as the
Arg228 side chain being displaced by 2.7 Å to create a strong
salt-bridge interaction with inhibitor carboxylate, while the side
chain of Tyr67 was folded over deeper into the active site
cavity (∼60°) and rotated (∼75°) to align with the inhibitor’s
phenyl moiety and create a strong aromatic interaction.
Additional interactions were found to stabilize inhibitor
binding, including a H-bond involving one sulfonamide oxygen
with the backbone nitrogen of Asn233, a residue conserved in
all subclass B1 MBLs and whose role is critical to properly
orient the β-lactam substrate.
Scaffold-Hopping from Pyridine to Thiazole and
Considerable Activity Improvement. As mentioned
above, as part of the initial chemistry exploration, we
investigated alternatives to the pyridine ring while keeping a
Figure 1.Mode of binding of 2,4-pyridine dicarboxylic acid (green) in
the active site of CphA (PDB code 2GKL) showing the coordination
to the single Zn ion.
Scheme 2. General Synthetic Routes Used to Prepare
Compounds Based on the Pyridine-2-carboxylic Acid
Scaffolda
a(a) R1CO2H, HATU, Et3N, then LiOH; (b) R2SO2Cl, Et3N, then
LiOH; (c) ArB(OH)2 and (Ph3P)4P, then LiOH; (d) R3NH2,
HATU, Et3N, then LiOH.
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“pyridine-like” nitrogen adjacent to the carbon bearing the
carboxy group. Several different heterocyclic replacements in
combination with the best side chains were explored. All but
one of the potential heterocyclic replacements showed worse
activity than pyridine (data not shown); however, encourag-
ingly, the thiazole analogues showed a significant and
consistent improvement over the corresponding pyridine
analogues, in terms of both in vitro enzyme inhibition and
whole-cell meropenem potentiation (Table 2 and Figures 3
and 4)
Table 1. Selected Pyridine-2-carboxylate Analogues (Full Table Can Be Found in the Supplementary Information)a
aAll IC50 values reported herein are the average of at least two independent assays. All reported IC50 values have R
2 values of >0.95 of the fitting
curve.
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.8b00246
ACS Infect. Dis. 2019, 5, 131−140
134
Several points emerge from this SAR analysis. First, trends
are easier to identify in the activity observed against NDM-1
clinical strains because these are generally much more resistant
than VIM-1- or IMP-1-producing clinical strains,19 and hence,
there is a bigger window in which to observe changes in
activity. Second, it is difficult to determine whether improve-
ments are due solely to changes in enzyme inhibition or also
due to better penetration into (or lack of efflux from) the
periplasm. To help identify compounds that have an improved
ability to penetrate into bacterial cells we have defined a new
term we call the “potentiation efficiency” (PE) for each
compound. This empirical term is calculated by dividing the
potentiated MIC for an MBL-producing strain by the IC50 for
the respective purified enzyme (PE = MIC/IC50), thus
“normalizing” the whole cell potentiation with respect to
enzyme activity such that the smaller the PE the better a
compound is accessing the periplasm, independent of the
actual enzyme inhibition. For example, if we consider the
matched pair of 61 (pyridyl) and 62 (thiazolyl) analogues,
Figure 2. X-ray structure of VIM-2 inhibited by 32. (A) Close view of
the VIM-2 active site (protein secondary structure elements and the
active-site residues are shown in green, surrounded by the 2Fo−Fc
Fourier map, blue meshes, contoured at 2 σ) in complex with
compound 32 (shown in cyan and surrounded by the omit Fo−Fc
map, green meshes, contoured at 3 σ). (B) Close-up view of the VIM-
2 active site showing the network of interactions between the
inhibitor (cyan), the Zn2 ion and residues Arg228 and Asn233. (C)
Orthogonal view of panel B and superimposition with the VIM-2
native structure (PDB code 1KO3, orange) showing the significant
movements of the side chains of residues Phe61, Tyr67, and Arg228
(green sticks) upon the binding of 32 (cyan).
Table 2. Comparison of IC50 Values and Meropenem
Potentiation Data for Matched Pairs of Pyridyl (A) and
Thiazolyl (B) Analogues
aNDM-1-producing strain Escherichia coli NTBC121 (MICMEM, 32
μg/mL). bVIM-1-producing strain Klebsiella pneumoniae NTBC055
(MICMEM, 16 μg/mL).
cIMP-1-producing strain K. pneumoniae
NTBC062 (MICMEM, 4 μg/mL).
dThe inhibitor was present at 100
μM.
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then it is clear that the thiazolyl derivative has improved NDM-
1 enzyme inhibitory activity (IC50 4.5 μM versus 49.9 μM) and
also improved meropenem potentiation against a correspond-
ing NDM-1 strain (MIC 0.125 μg/mL versus 16 μg/mL). The
corresponding PE values for 61 and 62 are 0.32 and 0.027,
respectively, showing that in this instance there is a 10-fold
improvement in potentiation over and above what might be
expected from the increase in enzyme inhibition alone,
suggesting that introduction of the thiazole has a profound
effect on both enzyme inhibition and bacterial penetration.
Although we are using this metric in the situation in which the
inhibitors have no intrinsic antibacterial activity, in principle,
the PE function should have wide applicability in antibacterial
research in which penetration into the periplasm or the
cytoplasm is a prerequisite for antibacterial action. The
limitation, of course, is that it does not give information as
to whether penetration or efflux is an issue but it can be a
useful empirical tool to facilitate SAR analysis and the direction
of the medicinal chemistry. The reason for the differences
between pyridyl and thiazolyl analogues is unclear at this
juncture.
A crystal structure of VIM-2 in complex with thiazole (62)
was also obtained, which confirmed a similar mode of inhibitor
binding as 32, with the thiazole nitrogen atom interacting
exclusively with Zn2 (Figure 5) and the carboxylate interacting
with both Arg228 and Zn2. However, the substituted
sulfonamide has adopted a slightly different conformation
compared to that observed in the complex with (32) (Figure
5). In this alternative binding mode, one oxygen atom of the
sulfonamide linker still interacts with the backbone nitrogen of
Asn233 but the phenyl group is interacting with Phe61 instead
of Tyr67. The side chain of the latter occupies a position
similar to that found in the native structure, while Phe61 is
slightly rotated and displaced upon binding of 62.
Moving from Phenyl Sulfonamide to Pyridyl Sulfo-
namide and Improvement of Solubility of the Acid
Form. Alongside improving compound activity, we also
focused on improving the physicochemical profile and in
particular aqueous solubility. The aqueous solubility of the key
compound 62 was determined as 1.1 mg/mL, whereas a
solubility of at least 10 mg/mL would be required to deliver a
therapeutically effective intravenous dose in an acceptable
volume of the aqueous vehicle. A standard approach to
increasing polarity and aqueous solubility is to add nitrogen
atoms into a phenyl ring. Consequently, we prepared a small
set of analogues set of side-chain pyridyl analogues of 62. A
total of two of the three aza analogues had improved enzyme
inhibition against NDM-1 (Table 3), and furthermore, the
Figure 3. Comparison of NDM-1 IC50 values for matched pairs of pyridyl (blue) and thiazolyl (green) analogues.
Figure 4. Comparison of meropenem potentiation data for matched pairs of pyridine (blue) and thiazole (green) analogues.
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most active compound (76) facilitated a meropenem MIC of
0.06 μg/mL against one of our NDM-1 producing clinical
strains (E. coli NTBC121) when tested in the presence of 100
μM inhibitor compared to an MIC of 0.125 μg/mL for 62. The
solubility of the side-chain pyridyl analogue (2.4 mg/mL) was
double that of the phenyl analogue 62, and conversion to the
sodium salt improved the solubility to almost 20 mg/mL
(Table 3), achieving the target solubility for testing in animal
efficacy studies.
The X-ray structure of VIM-2 bound to (76) showed a
broadly similar set of interactions to that of compounds 32 and
62 (Figure 6), with the sulfonamide substituent located
between residues Phe61 and Tyr67, inducing a significant
rotation of the side chain of the latter. Overall, these structural
data, which highlight a salt bridge interaction between the
negatively charged carboxylate group of the inhibitor and the
positively charged side chain of Arg228 could provide, to some
extent, a rationale for the overall lower activity of these
compounds (Table 3) on VIM-1. Indeed, Arg228 (whose role
can be assumed by Lys224 present in NDM-1 and IMP-1) is
replaced by a serine residue in VIM-1, in which this interaction
will be very likely abolished.
■ CONCLUSIONS
Our approach to the problem of antibiotic resistance due to
the emergence of MBL-producing Gram-negative pathogens
has been to undertake a medicinal chemistry campaign to
develop MBL inhibitors starting from pyridine-2-carboxylic
acid (1). Early array chemistry expanded the MBL coverage
from NDM-1 to encompass VIM-1, VIM-2, and IMP-1 while
also introducing whole cell activity such as to restore the
antibiotic activity of meropenem against clinical strains of
MBL-producing Enterobacteriaceae. Key benefits of this
approach over a nonspecific metal chelation approach (such
as using EDTA) are that off-target human toxicities are
minimized and the fact that newer NDM variants, due to
increased Zn affinity, are less susceptible to compounds that
depend on stripping Zn from the enzyme active site.20−22
A leap in both enzyme inhibition and potentiation was
achieved by switching from pyridine to the thiazole scaffold. As
shown from its increased PE value, the thiazolyl series exhibits
improved penetration into the bacterial periplasm as well as
improved enzyme inhibition. Additionally, although a modest
improvement to kinetic solubility was obtained by moving
from a side-chain phenyl sulfonamide to a side-chain pyridyl
Figure 5. X-ray structure of VIM-2 inhibited by 62. (A) Close view of
the VIM-2 active site (protein secondary structure elements and the
active site residues are shown in blue, surrounded by the 2Fo−Fc
Fourier map, blue meshes, contoured at 2 σ) in complex with 62
(shown in magenta and surrounded by the omit Fo−Fc map, green
meshes, contoured at 3 σ). (B) Binding of 62 in the enzyme active site
relies on a similar set of interactions between the thiazole moiety,
Zn2, and the Arg228 side chain. (C) Comparison of the substituted
sulfonamide conformation of 62, thiazole (magenta) and 32, pyridine
(cyan); the position of Phe61 and Tyr67 in the native VIM-2 is
shown in orange.
Table 3. Enzyme Inhibition, Potentiation, and Solubility of Side-Chain Phenyl and Pyridyl Analogues
compound X Y Z
NDM-1 IC50 μM
(MEM MIC, μg/mL)a
VIM-1 IC50
μM
IMP-1 IC50
μM
VIM-2 IC50
μM
solubility, mg/mLb (Na
salt)
75 N CH CH 12.9 >200 113.7 16.1 N/D
76 CH N CH 2.67 (0.06) >200 54.0 6.7 2.4 (16.9)
77 CH CH N 3.4 180 23.4 1.8 ND
62 CH CH CH 4.5 (0.125) >200 58.2 6.2 1.1 (18.9)
aNDM-1-producing strain E. coli NTBC121 (MEM MIC, 32 μg/mL). The inhibitor was present at 100 μM. bSolubility was determined in
phosphate-buffered saline (PBS) at pH 7.4.
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sulfonamide, greater improvements were achieved on making
the sodium salt, enabling formulation at sufficiently high
concentrations in aqueous buffers to perform efficacy testing in
animal models. Full biological characterization of compound
(76) (designated as ANT431) has recently been reported
elsewhere, demonstrating it to potentiate meropenem activity
against a panel of 94 randomly selected NDM- and VIM-
producing clinical strains and restore the efficacy of
meropenem in an E. coli (IR3) murine thigh infection
model.23 It should be pointed out that the potentiation of
meropenem by ANT431 is reported here at 100 μM inhibitor
concentration because that was the concentration we routinely
operated at during the early stages of this project. In fact,
ANT431 is effective at 28 μM (8 μg/mL).23 Further research
is underway to optimize this promising chemical series and
deliver a preclinical development candidate.
■ METHODS AND MATERIALS
Antimicrobial Susceptibility Testing. Minimal inhib-
itory concentrations (MIC) were determined using the Clinical
Laboratory Standards Institute (CLSI) broth microdilution
procedure. MBL-positive Enterobacteriaceae clinical isolates
tested in the susceptibility study included NDM-1-producing
strain E. coli NTBC121, VIM-1-producing strain K. pneumoniae
NTBC055, and IMP-1-producing strain K. pneumoniae
NTBC062. (Individual MICs for all strains tested are
presented in Table 2 and Table 1 in the Supporting
Information).
In Vitro Enzyme Inhibition Assays. Inhibition against
purified MBLs24 were determined by following hydrolysis of
300 μM imipenem in 10 mM HEPES (pH 7.5) buffer (25 °C)
in the presence of 0.025 to 500 μM inhibitor using a
PerkinElmer Envision (UV absorbance: 290 nm). Percentage
of enzymatic inhibition is calculated for each concentration
tested and reported on a nonlinear regression versus the
logarithmic concentration of inhibitors. The IC50 value is
determined from the regression curve only when the R2 of the
fitting curve is >0.95. The average of a minimum of at least 2
replicates is therefore reported.
Kinetic Solubility. This was determined by vigorous
stirring (1200 rpm) of a 20 mg/mL mixture of the test
compound in phosphate-buffered saline (PBS) at pH 7.4 for 4
h. The mixture was then centrifuged for 20 min at 10 000 rpm
and the supernatant further processed by filtration. The
concentration of the test compound in the filtrate was then
determined by high-performance liquid chromatography (UV
analysis) by comparison to a standard calibration curve of the
test compound.
X-ray Crystallography. The VIM-2 MBL was produced,
purified, and crystallized essentially as previously de-
scribed.25,26 The experimental details of protein crystallization,
crystal soaking, data collection, reduction, and refinement
(performed using the procedures described elsewhere)26 are
reported in the Supporting Information. Omit maps of the
three inhibitors bound to VIM-2 are shown in Figures 2, 5 and
6. Coordinates and structure factors of VIM-2 in complex with
inhibitors ANT-090 (32), ANT-330 (62), and ANT-431 (76)
were deposited in the RCSB Protein Data Bank under the
accession codes 5MXQ, 5MXR, and 6HF5, respectively.
Synthesis of Sodium 5-(Pyridine-3-sulfonamido)-1,3-thia-
zole-4-carboxylate (ANT431, Na Salt). Ethyl 5-amino-1,3-
thiazole-4-carboxylate, pyridine-3-sulfonyl chloride and all
other reagents and solvents were purchased and used as
such. 1H nuclear magnetic resonance (NMR) spectra were
obtained at 400 MHz in deuterated CDCl3 or DMSO-d6
solutions (reported in ppm). 13C NMR spectra were obtained
at 100 MHz in DMSO-d6, When peak multiplicities are
reported, the following abbreviations are used: s (singlet), d
(doublet), t (triplet), m (multiplet), dd (doublet of doublets),
dt (doublet of triplets), and q (quartet). Coupling constants
are reported in hertz (Hz).
Figure 6. X-ray structure of VIM-2 inhibited by 76. (A) Close view of
the VIM-2 active site (protein secondary structure elements and the
active site residues are shown in pink, surrounded by the 2Fo−Fc
Fourier map, blue meshes, contoured at 2 σ) in complex with 62
(shown in green and surrounded by the omit Fo−Fc map, green
meshes, contoured at 3 σ). (B) Close view of the VIM-2 active site
(pink) inhibited by 76 (light green). (C) Overlay of inhibitors 32
(cyan), 62 (magenta), and 76 (light green) in the VIM-2 active site,
showing the conserved interactions between the inhibitor and Zn2,
Arg228, and Asn233; the binding of 76 also induces the rotation of
the Tyr67 side chain to accommodate the pyridyl sulfonamide
substituent (native VIM-2 shown in orange).
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Ethyl 5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-carboxy-
late. To a stirred suspension of sodium hydride (60%
dispersion in oil) (929 mg, 23.22 mmol) in tetrahydrofuran
(50 mL) was added a solution of ethyl 5-amino-1,3-thiazole-4-
carboxylate (2 g, 11.61 mmol) in tetrahydrofuran (50 mL) at 0
°C under N2 atmosphere. The resulting reaction mixture was
stirred for 30 min at 0 °C and then treated with pyridine-3-
sulfonyl chloride (2.47 g, 13.93 mmol) in tetrahydrofuran (3
mL) in a drop-wise manner at 0 °C. The resulting reaction
mixture was stirred at room temperature for 3 h, then
quenched with ice, diluted with water, and washed with 50%
ethyl acetate in hexane (100 mL). The aqueous layer was
separated, neutralized with 1 N HCl solution, and extracted
with ethyl acetate (2 × 100 mL). The combined organic layers
were dried over anhydrous Na2SO4, filtered, and concentrated
to obtain the crude product. This was purified by column
chromatography on silica gel using 1−10% methanol in
dichloromethane (Rf 0.1 with 10% methanol in dichloro-
methane) as eluent to give the title compound as a yellow solid
(1.0 g, 27%). 1H NMR (CDCl3, 400 MHz, δ): 10.26 (s, 1H),
9.12 (d, J = 2.0 Hz, 1H), 8.83 (dd, J = 4.8, 1.2 Hz, 1H), 8.31
(s, 1H), 8.19−8.16 (m, 1H), 7.46 (dd, J = 8.0, 4.8 Hz, 1H),
4.39 (q, J = 7.2 Hz, 2H), 1.39 (t, J = 7.2 Hz, 3H). m/z: 314.0
[M + H]+.
5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-carboxylic acid
(ANT431). To a stirred solution of ethyl 5-(pyridine-3-
sulfonamido)-1,3-thiazole-4-carboxylate (1.0 g, 3.19 mmol)
in a mixture of tetrahydrofuran and water (10:5 in milliliters)
was added LiOH.H2O (1.33 g, 31.9 mmol) at room
temperature. The resulting reaction mixture was stirred at
room temperature for 48 h and then concentrated under
vacuum. The crude residue was diluted with water (30 mL)
and washed with ethyl acetate (30 mL). The aqueous layer was
acidified with 1 N HCl solution to pH4. The resulting
precipitation was filtered and dried under high vacuum to
obtain the title compound as a yellow solid (0.85g, 93%). 1H
NMR (DMSO-d6, 400 MHz, δ): 8.94 (d, J = 2.0 Hz, 1H), 8.79
(dd, J = 4.8, 1.2 Hz, 1H), 8.50 (s, 1H), 8.18 (td, J = 8.0, 2.0
Hz, 1H), 7.61 (dd, J = 8.0, 4.8 Hz, 1H). m/z: 286.0 [M + H]+.
Sodium 5-(Pyridine-3-sulfonamido)-1,3-thiazole-4-car-
boxylate (ANT431, Na Salt). To a solution of 5-(pyridine-3-
sulfonamido)-1,3-thiazole-4-carboxylic acid (850 mg, 2.98
mmol) in tetrahydrofuran (20 mL) was added 0.1 M sodium
hydroxide (29.8 mL, 2.98 mmol) solution and sonicated for 10
min to get a clear solution. Water (60 mL) was added, and the
mixture was lyophilized to obtain the title compound as a light
brown solid (890 mg, 97%) with a melting point of 297−300
°C. 1H NMR (DMSO-d6, 400 MHz, δ): 13.33 (s, 1H), 8.88 (s,
1H), 8.65 (d, J = 4 Hz, 1H), 8.08 (d, J = 8 Hz, 2H), 7.49 (dd, J
= 8.0, 4.8 Hz, 1H); 13C NMR (DMSO-d6, 100 MHz, δ):
163.94, 155.34, 151.77, 146.56, 140.16, 139.54, 133.88, 128.77,
123.95. m/z: 284.0 [M − Na]−. High-resolution electrospray
ionization mass spectrometry (m/z): [M − Na] calcd for
C9H6O4N3S2, 283.9794; found, 283.9735.
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Gonzaĺez, L. J., and Vila, A. J. (2017) Clinical Evolution of New Delhi
Metallo-β-Lactamase (NDM) Optimizes Resistance under Zn(II)
Deprivation. Antimicrob. Agents Chemother. 62 (1), e01849−17.
(21) Cheng, Z., Thomas, P. W., Ju, L., Bergstrom, A., Mason, K.,
Clayton, D., Miller, C., Bethel, C. R., VanPelt, J., Tierney, D. L., Page,
R. C., Bonomo, R. A., Fast, W., and Crowder, M. W. (2018) Evolution
of New Delhi metallo-β-lactamase (NDM) in the clinic: effects of
NDM mutations on stability, zinc affinity, mono-zinc activity. J. Biol.
Chem. 293, 12606−12618.
(22) Ju, L. C., Cheng, Z., Fast, W., Bonomo, R. A., and Crowder, M.
W. (2018) The Continuing Challenge of Metallo-β-Lactamase
Inhibition: Mechanism Matters. Trends Pharmacol. Sci. 39 (7),
635−647.
(23) Everett, M., Sprynski, N., Coelho, A., Castandet, J., Bayet, M.,
Lozano, C., Davies, D. T., Leiris, S., Zalacain, M., Morrissey, I.,
Magnet, S., Holden, K., Warn, P., De Luca, F., Docquier, J.-D.,
Lemonnier, M., and Bougnon, J. (2018) Discovery of a novel metallo-
β-lactamase inhibitor, which can potentiate Meropenem activity
against carbapenem-resistant Enterobacteriaceae. Antimicrob. Agents
Chemother. 62 (5), e00074−18.
(24) Docquier, J.-D., Lamotte-Brasseur, J., Galleni, M., Amicosante,
G., Frer̀e, J. M., and Rossolini, G. M. (2003) On functional and
structural heterogeneity of VIM-type metallo-β-lactamases. J.
Antimicrob. Chemother. 51, 257−266.
(25) Garcia-Saez, I., Docquier, J.-D., Rossolini, G. M., and Dideberg,
O. (2008) The three-dimensional structure of VIM-2, a Zn-β-
lactamase from Pseudomonas aeruginosa in its reduced and oxidised
form. J. Mol. Biol. 375, 604−611.
(26) Docquier, J.-D., Benvenuti, M., Calderone, V., Stoczko, M.,
Menciassi, N., Rossolini, G. M., and Mangani, S. (2010) High-
resolution crystal structure of the subclass B3 metallo-β-lactamase
BJP-1: rational basis for substrate specificity and interaction with
sulfonamides. Antimicrob. Agents Chemother. 54, 4343−4351.
ACS Infectious Diseases Article
DOI: 10.1021/acsinfecdis.8b00246
ACS Infect. Dis. 2019, 5, 131−140
140
